Antibacterial discovery and development—the failure of success?

A combination of approaches and compounds—many of which failed to yield immediate results in the past—will ultimately prove invaluable to the drug industry in the ongoing battle against infectious disease.

[1]  J. Mekalanos,et al.  In vivo expression technology for selection of bacterial genes specifically induced in host tissues. , 1994, Methods in enzymology.

[2]  Siewert J Marrink,et al.  Antimicrobial peptides in action. , 2006, Journal of the American Chemical Society.

[3]  A. Bayer,et al.  Linezolid: a new antibiotic. , 2000, Drugs of Today.

[4]  Kinase inhibitors: Surveying the kinome , 2005, Nature Reviews Drug Discovery.

[5]  R. Owens,et al.  Antimicrobial safety: focus on fluoroquinolones. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  Christoph Freiberg,et al.  Functional genomics in antibacterial drug discovery. , 2005, Drug discovery today.

[7]  M. Pucci.  Use of genomics to select antibacterial targets. , 2006, Biochemical pharmacology.

[8]  Zhengyu Yuan,et al.  The evolution of peptide deformylase as a target: contribution of biochemistry, genetics and genomics. , 2006, Biochemical pharmacology.

[9]  C. Nathan,et al.  The profit problem in antibiotic R&D , 2005, Nature Reviews Drug Discovery.

[10]  M. Waldor.  Disarming pathogens--a new approach for antibiotic development. , 2006, The New England journal of medicine.

[11]  M. Schmid.  Crystallizing new approaches for antimicrobial drug discovery. , 2006, Biochemical pharmacology.

[12]  P. Fernandes.  The ATCG of drug discovery. , 2000, Current opinion in molecular therapeutics.

[13]  M. Kollef.  Is antibiotic cycling the answer to preventing the emergence of bacterial resistance in the intensive care unit? , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  S. Schreiber,et al.  Target-oriented and diversity-oriented organic synthesis in drug discovery. , 2000, Science.

[15]  Sheo B Singh,et al.  Empirical antibacterial drug discovery--foundation in natural products. , 2006, Biochemical pharmacology.

[16]  Ken Dewar,et al.  A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. , 2005, The New England journal of medicine.

[17]  M. Jacobs,et al.  Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. , 2005, Current opinion in microbiology.

[18]  J. Brieland,et al.  Synthesis via Inhibition of Mitochondrial Protein Oxazolidinones Inhibit Cellular Proliferation , 2005 .

[19]  S. Wilhelm,et al.  Discovery and development of sorafenib: a multikinase inhibitor for treating cancer , 2006, Nature Reviews Drug Discovery.

[20]  P. Fernandes,et al.  The frequency of in-vitro resistance development to fluoroquinolones and the use of a murine pyelonephritis model to demonstrate selection of resistance in vivo. , 1987, The Journal of antimicrobial chemotherapy.

[21]  P. Fernandes,et al.  Chapter 12 Quinolones , 1987 .

[22]  H. Gold,et al.  Antimicrobial resistance to linezolid. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  Antipneumococcal Activity of DW-224a, a New Quinolone, Compared to Those of Eight Other Agents , 2006, Antimicrobial Agents and Chemotherapy.

[24]  Ronald N. Jones,et al.  Worldwide Antimicrobial Susceptibility Patterns and Pharmacodynamic Comparisons of Gatifloxacin and Levofloxacin against Streptococcus pneumoniae: Report from the Antimicrobial Resistance Rate Epidemiology Study Team , 2003, Antimicrobial Agents and Chemotherapy.

[25]  H. H. Xu,et al.  An array of Escherichia coli clones over-expressing essential proteins: a new strategy of identifying cellular targets of potent antibacterial compounds. , 2006, Biochemical and biophysical research communications.

[26]  Heinz G Floss,et al.  Combinatorial biosynthesis--potential and problems. , 2006, Journal of biotechnology.

[27]  J. Sutcliffe.  Improving on nature: antibiotics that target the ribosome. , 2005, Current opinion in microbiology.

[28]  R. Monaghan,et al.  Antibacterial drug discovery--then, now and the genomics future. , 2006, Biochemical pharmacology.

[29]  T J O'Donnell,et al.  Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug--DNA binding model. , 1989, Biochemistry.

[30]  N. Wallis,et al.  The impact of genomics on novel antibacterial targets. , 2000, Current opinion in drug discovery & development.

[31]  Edward N Baker,et al.  The potential impact of structural genomics on tuberculosis drug discovery. , 2006, Drug discovery today.

[32]  P. Fernandes,et al.  In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile , 1991, Antimicrobial Agents and Chemotherapy.

[33]  M. Schmid.  Do targets limit antibiotic discovery? , 2006, Nature Biotechnology.

[34]  Mark S Butler,et al.  Natural products--the future scaffolds for novel antibiotics? , 2006, Biochemical pharmacology.

[35]  F. Peláez.  The historical delivery of antibiotics from microbial natural products--can history repeat? , 2006, Biochemical pharmacology.

[36]  Judy Halliday,et al.  Targeting the forgotten transglycosylases. , 2006, Biochemical pharmacology.

[37]  R. Sykes,et al.  Monocyclic β‐lactam antibiotics , 1984 .

[38]  A. Robicsek,et al.  The worldwide emergence of plasmid-mediated quinolone resistance. , 2006, The Lancet. Infectious diseases.

[39]  D. Hughes,et al.  Sampling the Antibiotic Resistome , 2006, Science.

[40]  S. Lory,et al.  Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen , 2000, Nature.

[41]  J. Buysse.  The role of genomics in antibacterial target discovery. , 2001, Current medicinal chemistry.

[42]  R. Wenzel,et al.  The antibiotic pipeline--challenges, costs, and values. , 2004, The New England journal of medicine.

[43]  P. Higgins,et al.  Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-beta-naphthylamide. , 2006, The Journal of antimicrobial chemotherapy.

[44]  Thomas Hermann,et al.  Structure-Guided Discovery of Novel Aminoglycoside Mimetics as Antibacterial Translation Inhibitors , 2005, Antimicrobial Agents and Chemotherapy.

[45]  A. Alanis,et al.  Resistance to antibiotics: are we in the post-antibiotic era? , 2005, Archives of medical research.

[46]  J. Baranowski,et al.  Mechanism of inhibition of DNA gyrase by quinolone antibacterials: specificity and cooperativity of drug binding to DNA. , 1989, Biochemistry.

[47]  P. Selzer,et al.  Target-based drug discovery for the development of novel antiinfectives. , 2000, International journal of medical microbiology : IJMM.

[48]  P. Ball.  Adverse drug reactions: implications for the development of fluoroquinolones. , 2003, The Journal of antimicrobial chemotherapy.

[49]  R. Lenski,et al.  Bacterial evolution and the cost of antibiotic resistance. , 1998, International microbiology : the official journal of the Spanish Society for Microbiology.

[50]  K. Reynolds,et al.  Production of hygromycin A analogs in Streptomyces hygroscopicus NRRL 2388 through identification and manipulation of the biosynthetic gene cluster. , 2006, Chemistry & biology.

[51]  A. Fauci,et al.  The challenge of emerging and re-emerging infectious diseases , 2004, Nature.

[52]  A. Meyer.  Prospects and challenges of developing new agents for tough Gram-negatives. , 2005, Current opinion in pharmacology.

[53]  H. Giamarellou.  Treatment options for multidrug-resistant bacteria , 2006, Expert review of anti-infective therapy.

[54]  Jun Wang,et al.  Platensimycin is a selective FabF inhibitor with potent antibiotic properties , 2006, Nature.

[55]  Erin M Duffy,et al.  Structure-based drug design meets the ribosome. , 2006, Biochemical pharmacology.

[56]  S. Levy,et al.  Inter- and intraspecies spread of Escherichia coli in a farm environment in the absence of antibiotic usage. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[57]  Guang Yang,et al.  Glycopeptides: Update on an old successful antibiotic class. , 2006, Biochemical pharmacology.

[58]  C. Ash.  Antibiotic resistance: the new apocalypse? , 1996, Trends in microbiology.

[59]  S. D. Mills.  When will the genomics investment pay off for antibacterial discovery? , 2006, Biochemical pharmacology.

[60]  Roberta B Carey,et al.  Methicillin-resistant S. aureus infections among patients in the emergency department. , 2006, The New England journal of medicine.

[61]  D. Gerding,et al.  Clostridium difficile--associated diarrhea. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[62]  N. Woodford,et al.  Biological counterstrike: antibiotic resistance mechanisms of Gram-positive cocci. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[63]  H. Neu,et al.  Clavulanic Acid, a Novel Inhibitor of β-Lactamases , 1978, Antimicrobial Agents and Chemotherapy.

[64]  A. P. Sergeyko,et al.  Rational design of macrolides by virtual screening of combinatorial libraries generated through in silico manipulation of polyketide synthases. , 2006, Journal of medicinal chemistry.

[65]  P. Rochon,et al.  Are Broad-Spectrum Fluoroquinolones More Likely To Cause Clostridium difficile-Associated Disease? , 2006, Antimicrobial Agents and Chemotherapy.

[66]  A. Rodloff,et al.  In Vitro Activity of OPT-80 against Clostridium difficile , 2004, Antimicrobial Agents and Chemotherapy.

[67]  N. Jacobus,et al.  In Vitro and In Vivo Antibacterial Activities of a Novel Glycylcycline, the 9-t-Butylglycylamido Derivative of Minocycline (GAR-936) , 1999, Antimicrobial Agents and Chemotherapy.

[68]  P. Petersen,et al.  Synthesis and antibacterial activity of 9-substituted minocycline derivatives. , 2006, Bioorganic & medicinal chemistry letters.

[69]  R. Copeland,et al.  Biochemical Characterization of the Interactions of the Novel Pleuromutilin Derivative Retapamulin with Bacterial Ribosomes , 2006, Antimicrobial Agents and Chemotherapy.

[70]  Amit Singh,et al.  Dissecting virulence pathways of Mycobacterium tuberculosis through protein-protein association. , 2006, Proceedings of the National Academy of Sciences of the United States of America.